Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3916389 | 0.85 | SMN1; SMN2 (0.40) | KDM4EALDH1A1SMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL11821021 | 0.81 | MCL1 (0.34) | KDM4EALDH1A1 | |
| SCHEMBL28261770 | 0.80 | ALDH1A1 (0.42) | KDM4EALDH1A1SMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL18618110 | 0.79 | — | — | |
| SCHEMBL22365839 | 0.78 | SMN1; SMN2 (0.44) | KDM4EALDH1A1SMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL15052626 | 0.78 | SMN1; SMN2 (0.44) | KDM4EALDH1A1SMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL283932 | 0.78 | SMN1; SMN2 (0.44) | KDM4EALDH1A1SMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL20002868 | 0.76 | ALDH1A1 (0.39) | KDM4EALDH1A1SMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL6879374 | 0.76 | ALDH1A1 (0.39) | KDM4EALDH1A1SMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL16892259 | 0.76 | ALDH1A1 (0.39) | KDM4EALDH1A1SMN1; SMN2L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002072571-A2 | PYRIDINYL PYRAZOLES USEFUL FOR THE TREATMENT OF COPD | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-19 | — | — | WO | claimed |
| US-20230278997-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| CN-116438166-A | N-substituted 4- (1, 3-aryloxazol-2-yl) phenyl compounds for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-103052386-B | Compositions containing tetracyclic compound | CHUGAI PHARMACEUTICAL CO.,LTD. (JP) | 2016-03-02 | — | — | CN | disclosed |
| EP-2483277-B1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-12-02 | — | — | EP | disclosed |
| CN-102762574-B | Benzoxapi 3K inhibitor compounds and methods of use | HOFFMAN-LA ROCHE LTD. (CH) | 2015-12-02 | — | — | CN | disclosed |
| US-9175009-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| CN-104987345-A | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE | 2015-10-21 | — | — | CN | disclosed |
| CN-102459172-B | Tetracyclic compound | CHUGAI PHARMACEUTICAL CO LTD | 2015-06-24 | — | — | CN | disclosed |
| US-20150094347-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-04-02 | — | — | US | disclosed |
| US-8952043-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | GENETECH, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2784078-A1 | Benzoxepin pi3k inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-20140135308-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8673952-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20130012488-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BLAQUIERE NICOLE (US) | 2013-01-10 | — | — | US | disclosed |
| CN-102762574-A | Benzoxapi 3K inhibitor compounds and methods of use | HOFFMANN LA ROCHE | 2012-10-31 | — | — | CN | disclosed |
| US-8263633-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2012-09-11 | — | — | US | disclosed |
| EP-2483277-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012488-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3R2 | KDM4E 2757/4885ALDH1A1 4119/4885SMN1; SMN2 2293/4885 |
| US-20150094347-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, NR2E1, NR2E3 | KDM4E 3459/4885ALDH1A1 4809/4885SMN1; SMN2 1519/4885 |
| US-20140135308-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, NR2E1, NR2E3 | KDM4E 3459/4885ALDH1A1 4809/4885SMN1; SMN2 1519/4885 |
| US-20230278997-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP1B1, CYP7A1 | KDM4E 3906/4885ALDH1A1 79/4885SMN1; SMN2 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.